Last update 27 Mar 2025

Edoxaban Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
edoxaban, Edoxaban Tosilate, Edoxaban Tosilate Hydrate
+ [11]
Target
Action
inhibitors
Mechanism
factor Xa inhibitors(Factor Xa inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC31H40ClN7O8S2
InChIKeyPSMMNJNZVZZNOI-SJILXJHISA-N
CAS Registry1229194-11-9

External Link

KEGGWikiATCDrug Bank
-Edoxaban Tosylate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thromboembolism
Canada
04 Nov 2016
Atrial Fibrillation
European Union
19 Jun 2015
Atrial Fibrillation
Iceland
19 Jun 2015
Atrial Fibrillation
Liechtenstein
19 Jun 2015
Atrial Fibrillation
Norway
19 Jun 2015
Recurrent deep vein thrombosis
European Union
19 Jun 2015
Recurrent deep vein thrombosis
Iceland
19 Jun 2015
Recurrent deep vein thrombosis
Liechtenstein
19 Jun 2015
Recurrent deep vein thrombosis
Norway
19 Jun 2015
Systemic embolism
Switzerland
31 Mar 2015
Embolism
United States
08 Jan 2015
Stroke
United States
08 Jan 2015
Venous Thromboembolism
Japan
26 Sep 2014
Pulmonary Embolism
Japan
22 Apr 2011
Venous Thrombosis
Japan
22 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute myocardial infarctionPhase 3
Brazil
14 Sep 2021
Coronary Artery DiseasePhase 3
Brazil
14 Sep 2021
Short Chain Acyl CoA Dehydrogenase DeficiencyPhase 3
Brazil
14 Sep 2021
Chronic thromboembolic pulmonary hypertensionPhase 3
Japan
23 Mar 2021
COVID-19Phase 3
Belgium
21 Jan 2021
COVID-19Phase 3
Italy
21 Jan 2021
COVID-19Phase 3
Switzerland
21 Jan 2021
Aortic Valve StenosisPhase 3
Netherlands
01 Aug 2019
Heart DiseasesPhase 3
United States
15 May 2018
Heart DiseasesPhase 3
Austria
15 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
2,608
(Edoxaban)
puymoqiwxi = hfjiqeklxh utxecbcwlt (eugrflstyr, biupccpquv - eirnnwdqla)
-
06 Feb 2025
(ASA or Placebo)
puymoqiwxi = inbfqowenl utxecbcwlt (eugrflstyr, yvugaauagk - vbpxnvzogr)
Phase 4
-
mvgpiolxfy(cvcscfmdud): HR = 0.44 (95% CI, 0.3 - 0.65)
Positive
05 Dec 2024
Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
NEWS
ManualManual
Not Applicable
-
yqqmyvkyca(aqshzaxigu) = xsvhvlcuwr gffflpizqy (oljtwyletj )
Positive
19 Nov 2024
yqqmyvkyca(aqshzaxigu) = ydmmefjvxp gffflpizqy (oljtwyletj )
Not Applicable
-
hsamhyqbpd(hckfaodvoh) = heart failure due to valve thrombosis occurred in 2 cases pgatiwtvey (duuwqstesf )
-
02 Sep 2024
Not Applicable
-
(Moderate-to-low bleeding risk)
qayzwquykx(xpclnxydqh): HR = 3.27 (95% CI, 1.52 - 7.04)
-
31 Aug 2024
(High bleeding risk)
Not Applicable
-
kivqjepgyf(mjoasgebwi) = zskdlwsdcn byhkvuiaeg (zvkhxskscc )
-
31 Aug 2024
Phase 2/3
serum D-dimer level | microembolic signals detected by transcranial Doppler
40
Edoxaban 60 mg once daily
aaqjspshzc(kdltnsgyvu) = gxwmjplflv epmcxugbyc (ymhjwplbth )
Negative
01 Jul 2024
Enoxaparin 1 mg/kg twice daily
aaqjspshzc(kdltnsgyvu) = fkpuhsmxhw epmcxugbyc (ymhjwplbth )
Phase 4
-
dpbywnzaqd(uujyuqrshh) = qdahrhalpm dzkgeyogdb (bixuwdpuui )
Positive
22 Apr 2024
dpbywnzaqd(uujyuqrshh) = oboboqfgdk dzkgeyogdb (bixuwdpuui )
Not Applicable
2,448
On-label reduced-dose edoxaban
gtrjavnkcb(erhyeuwphp) = wkfvmbetak ykvlouuvoi (tecxcpyokm )
Positive
08 Apr 2024
(Non-octogenarian patients)
gtrjavnkcb(erhyeuwphp) = kzxegyfcxo ykvlouuvoi (tecxcpyokm )
Not Applicable
5,001
Edoxaban 60 mg OD
ehxgomgaao(tcnpdpgzxc) = ncearzuibu pjgxmklerl (rvnsdwqxgt )
Positive
08 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free